Valganciclovir for symptomatic congenital cytomegalovirus disease.

ABSTRACT:

Background

The treatment of symptomatic congenital cytomegalovirus (CMV) disease with intravenous ganciclovir for 6 weeks has been shown to improve audiologic outcomes at 6 months, but the benefits wane over time.

Methods

We conducted a randomized, placebo-controlled trial of valganciclovir therapy in neonates with symptomatic congenital CMV disease, comparing 6 months of therapy with 6 weeks of therapy. The primary end point was the change in hearing in the better ear ("best-ear" hearing) from baseline to 6 months. Secondary end points included the change in hearing from baseline to follow-up at 12 and 24 months and neurodevelopmental outcomes, with each end point adjusted for central nervous system involvement at baseline.

Results

A total of 96 neonates underwent ra

SUBMITTER: Kimberlin DW 

PROVIDER: S-EPMC4401811 | biostudies-literature | 2015 Mar

REPOSITORIES: biostudies-literature